Search results
Showing 31 to 45 of 83 results for atezolizumab
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
In development [GID-TA11197] Expected publication date: TBC
In development [GID-TA11289] Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
Awaiting development [GID-TA11299] Expected publication date: TBC
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
Awaiting development [GID-TA11438] Expected publication date: TBC
Awaiting development [GID-TA11021] Expected publication date: TBC
Awaiting development [GID-TA11502] Expected publication date: TBC
Awaiting development [GID-TA10777] Expected publication date: TBC
Atezolizumab for untreated advanced renal cell carcinoma [ID1365]
Discontinued [GID-TA10338]
Awaiting development [GID-TA11654] Expected publication date: TBC
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued [GID-TA10228]
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued [GID-TA10830]